menu
    • menu
    [{"orgOrder":0,"company":"XBiotech","sponsor":"BioBridge Global","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Human antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ BioBridge Global","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ BioBridge Global"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IH201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"IH201","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"5-fluorouracil","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2021","type":"Divestment","leadProduct":"Bermekimab","moa":"IL-1 alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"XBiotech","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"IL-1 alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CAR90972","moa":"IL-1 alpha","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"XB2001","moa":"","graph1":"Rheumatology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"The French National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Tipiracil","moa":"Il-1 alpha receptor","graph1":"Oncology","graph2":"Phase III","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ The French National Cancer Institute","highestDevelopmentStatusID":"10","companyTruncated":"XBiotech \/ The French National Cancer Institute"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"XB2001","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Hutrukin","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human IgG4 Monoclonal Antibody","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Vilamakitug","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Irinotecan","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"XBiotech \/ Not Applicable"},{"orgOrder":0,"company":"XBiotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Irinotecan","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"XBiotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"XBiotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XBiotech \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by XBiotech

    Menu

    XBiotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech's Phase 1/2 Study Shows Promise for Pancreatic Cancer

                            Details : Natrunix is an immunoglobulin cloned from healthy human donor which blocks IL-1α it is being investigated in combination with chemotherapy regimen for pancreatic cancer.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 18, 2024

                            Lead Product(s) : Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for...

                            Details : Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. is being developed to reduce brain injury following ischemic stroke.

                            Brand Name : Hutrukin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 26, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pa...

                            Details : Natrunix (vilamakitug) is a unique kind of drug, an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor, and is investigated in combination with chemotherapy for treating pancreatic cancer.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 30, 2023

                            Lead Product(s) : Vilamakitug,Irinotecan Hydrochloride,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vilamakitug

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical ...

                            Details : Natrunix (human IgG4 monoclonal antibody) is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor and blocks inflammation in rheumatoid arthritis.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 08, 2023

                            Lead Product(s) : Vilamakitug

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human IgG4 Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

                            Details : Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor and blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α).

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 22, 2023

                            Lead Product(s) : Human IgG4 Monoclonal Antibody

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hutrukin

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy ...

                            Details : Hutrukin therapy is intended to be provided immediately prior to the clot-busting procedure, where the drug may reduce inflammatory injury associated with reperfusion. is being developed to reduce brain injury following ischemic stroke.

                            Brand Name : Hutrukin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 17, 2023

                            Lead Product(s) : Hutrukin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XB2001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

                            Details : The Natrunix (XB2001), antibody therapy represents a groundbreaking approach to therapy—with the aim to of reducing treatment related toxicity of chemotherapy while also blocking the tumor-associated signals that spurn growth and spread of tumors.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 20, 2022

                            Lead Product(s) : XB2001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XB2001,Trifluridine,Tipiracil Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : The French National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Supp...

                            Details : Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic colorectal cancer in subjects that have failed earlier treatment with oxaliplatin, irinotecan, and fluoropyrimidine.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 28, 2022

                            Lead Product(s) : XB2001,Trifluridine,Tipiracil Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : The French National Cancer Institute

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XB2001

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves XBiotech’s IND in Rheumatology

                            Details : Natrunix is a new drug, discovered and manufactured at XBiotech’s research and development headquarters in Austin, Texas. The Company believes Natrunix holds promise as a breakthrough therapy for the treatment of inflammatory joint diseases.

                            Brand Name : Natrunix

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 13, 2021

                            Lead Product(s) : XB2001

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            XBiotech

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR90972

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XBiotech to Launch Novel Candidate Therapy for Stroke

                            Details : XBiotech True Human antibodies are derived without modification from individuals who possess natural immunity to certain diseases. True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, e...

                            Brand Name : CAR90972

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2021

                            Lead Product(s) : CAR90972

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth